CMS transparency rules and AI could bring “Expedia-like” drug price comparisons for consumers, but payer compliance to transparency rules remains low.
News|Articles|July 1, 2002
No decline in GI cotherapy or healthcare costs with switch to COX-2 selective drugs
Switching from traditional nonsteroidal anti-inflammatory drugs (NSAIDs) to COX-2 selective drugs does not result in a decrease in gastrointestinal (GI) medical cotherapy. Furthermore, there is no reduction in GI healthcare costs when patients are switched from NSAIDs to selective COX-2 inhibitors, said Loren Laine, MD, at Digestive Disease Week in San Francisco.
Advertisement
Advertisement
Related to this article
A new Spherix Global Insights survey shows providers want administrative support for prior authorization while patients prioritize access and affordability
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Billing for lab tests, especially genetic tests, is a mess. Bill Kerr has ideas about how to clean it up.
2
A conversation with Jordan Herring, Ph.D., and Carlos E. Rodriguez-Diaz, Ph.D., MPHE, MCHES, about the relationship between HIV incidence in Hispanic communities and immigration policy
3
Final GLOBE drug model projects much smaller savings while 2027 Part D premiums split
4
Closing the outpatient monitoring gap in cancer
5